• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.

作者信息

DeRenzo Christopher, Gottschalk Stephen

机构信息

Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pediatrics Baylor College of Medicine, Houston, Texas 77030, USA.

Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pediatrics Baylor College of Medicine, Houston, Texas 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.

出版信息

J Clin Cell Immunol. 2016 Apr;7(2). doi: 10.4172/2155-9899.1000417. Epub 2016 Apr 29.

DOI:10.4172/2155-9899.1000417
PMID:27313973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4904842/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905a/4904842/a23238d17da7/nihms787838f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905a/4904842/3d487386f297/nihms787838f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905a/4904842/a23238d17da7/nihms787838f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905a/4904842/3d487386f297/nihms787838f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905a/4904842/a23238d17da7/nihms787838f2.jpg

相似文献

1
Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.用于治疗骨肉瘤的基因改造T细胞疗法：最新进展
J Clin Cell Immunol. 2016 Apr;7(2). doi: 10.4172/2155-9899.1000417. Epub 2016 Apr 29.
2
Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.表达自体抗体嵌合抗原受体的自体 T 细胞可能成为骨肉瘤的一种新治疗方法。
Med Hypotheses. 2012 May;78(5):616-8. doi: 10.1016/j.mehy.2012.01.038. Epub 2012 Feb 12.
3
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.嵌合抗原受体 CD166/4-1BB 双靶点 T 细胞治疗骨肉瘤的研究进展
J Exp Clin Cancer Res. 2019 Apr 17;38(1):168. doi: 10.1186/s13046-019-1147-6.
4
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.表达 NKG2D-CAR 的记忆 T 细胞能有效靶向骨肉瘤细胞。
Clin Cancer Res. 2017 Oct 1;23(19):5824-5835. doi: 10.1158/1078-0432.CCR-17-0075. Epub 2017 Jun 28.
5
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.使用靶向癌症种系抗原MAGE-A3的主要组织相容性复合体II类限制性T细胞受体治疗转移性癌症患者
J Clin Oncol. 2017 Oct 10;35(29):3322-3329. doi: 10.1200/JCO.2017.74.5463. Epub 2017 Aug 15.
6
[Therapeutic approaches using genetically modified cells].[使用基因改造细胞的治疗方法]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1274-80. doi: 10.1007/s00103-015-2245-z.
7
Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer.腺病毒介导的B7-1/Fas嵌合基因转移同时诱导T细胞活化和骨肉瘤细胞凋亡
Cancer Gene Ther. 2003 Sep;10(9):717-25. doi: 10.1038/sj.cgt.7700624.
8
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.嵌合抗原受体工程：过继细胞免疫治疗进化过程中的正确步骤。
Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.
9
Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.目前提高嵌合抗原受体（CAR）修饰 T 细胞安全性的策略。
Immunol Lett. 2017 Oct;190:201-205. doi: 10.1016/j.imlet.2017.08.018. Epub 2017 Aug 29.
10
[Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].[使用嵌合抗原受体的基因修饰T细胞疗法治疗儿童血液系统恶性肿瘤]
Rinsho Ketsueki. 2016 Jun;57(6):701-8. doi: 10.11406/rinketsu.57.701.

本文引用的文献

1
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.CRISPR-Cas9介导对癌症患者人类原代T细胞进行有效的程序性死亡受体1（PD-1）基因敲除。
Sci Rep. 2016 Jan 28;6:20070. doi: 10.1038/srep20070.
2
Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity.嵌合抗原受体T细胞：提高其疗效并降低毒性的新方法。
Cancer J. 2015 Nov-Dec;21(6):475-9. doi: 10.1097/PPO.0000000000000155.
3
Smart CARs engineered for cancer immunotherapy.为癌症免疫疗法设计的智能嵌合抗原受体（CAR）细胞
Curr Opin Oncol. 2015 Nov;27(6):466-74. doi: 10.1097/CCO.0000000000000232.
4
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.α-CTLA-4 和 α-PD-L1 抗体阻断的联合免疫疗法可防止免疫逃逸，并导致转移性骨肉瘤的完全控制。
J Immunother Cancer. 2015 May 19;3:21. doi: 10.1186/s40425-015-0067-z. eCollection 2015.
5
TRUCKs: the fourth generation of CARs.靶向嵌合受体（TRUCKs）：第四代嵌合抗原受体（CARs）。
Expert Opin Biol Ther. 2015;15(8):1145-54. doi: 10.1517/14712598.2015.1046430. Epub 2015 May 18.
6
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.用于HER2阳性肉瘤免疫治疗的人表皮生长因子受体2（HER2）特异性嵌合抗原受体修饰的T细胞
J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.
7
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.通过抗PD-1/PD-L1相互作用抗体阻断增强对骨肉瘤的T细胞免疫。
J Immunother. 2015 Apr;38(3):96-106. doi: 10.1097/CJI.0000000000000065.
8
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.经基因工程改造的肿瘤浸润淋巴细胞，其携带可诱导的白细胞介素-12编码基因，用于转移性黑色素瘤的免疫治疗。
Clin Cancer Res. 2015 May 15;21(10):2278-88. doi: 10.1158/1078-0432.CCR-14-2085. Epub 2015 Feb 18.
9
Adoptive cell therapy for sarcoma.肉瘤的过继性细胞疗法。
Immunotherapy. 2015;7(1):21-35. doi: 10.2217/imt.14.98.
10
Genetically modified T-cell therapy for osteosarcoma.骨肉瘤的基因修饰 T 细胞治疗。
Adv Exp Med Biol. 2014;804:323-40. doi: 10.1007/978-3-319-04843-7_18.